RNAPc2 (Nuvelo)

Current Opinion in Investigational Drugs

Volumn 5, Issue 3, 2004, Pages 327-333

  Mungall, Dennis ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI COAGULANT PROTEIN C2, ANCYLOSTOMA CANINUM; ANTI-COAGULANT PROTEIN C2, ANCYLOSTOMA CANINUM; FIBRINOLYTIC AGENT; HELMINTH PROTEIN; RECOMBINANT PROTEIN;

ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION; VEIN THROMBOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; HUMANS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VENOUS THROMBOSIS;

EID: 3042678168     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. 201066 New generation of potential antithrombotic drugs from a hookworm described in proceedings of the National Academy of Sciences Corvas selects lead development candidate from novel class of small protein anticoagulants. Corvas International Inc PRESS RELEASE 1996 March 05
2. 224055 Ancylostoma caninum anticoagulant peptide: Cloning by PCR and expression of soluble, active protein in E coli. Cappello M, Hawdon JM, Jones BF, Kennedy WP, Hotez PJ MOL BIOCHEM PARASITOL 1996 80 1 113-117
3. 224057 Anticoagulant repertoire of the hookworm Ancylostoma caninum. Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ et al PROC NATL ACAD SCI USA 1996 93 5 2149-2154
4. 225767 Corvas presents data at American Heart Association meeting on antithrombotic agent NAPc2. Corvas International Inc PRESS RELEASE 1996 November 13
5. 264179 Corvas completes phase Ia clinical trial for NAPc2 anticoagulant. Corvas International Inc PRESS RELEASE 1997 September 24
6. 266827 Corvas reports third quarter results and initiation of phase Ib trial for rNAPc2. Corvas International Inc PRESS RELEASE 1997 October 21
7. 307912 Corvas begins phase II clinical trial for injectable anticoagulant, rNAPc2. Corvas International Inc PRESS RELEASE 1998 December 02
8. 310281 American Society of Hematology - 40th Annual Meeting (Part II), Miami, FL, USA. Sheth SB IDDB MEETING REPORT 1998 December 04-08
9. 313486 Corvas issued four US patents on recombinant nematode anticoagulant proteins (rNAPS). Corvas International Inc PRESS RELEASE 1999 February 03
10. 316440 Early clinical evaluation of rNAPc2, a novel inhibitor of blood coagulation Factor VIIa/tissue factor (FVIIa/TF). Vlasuk GP, Bradbury A, Bergum PW J AM COLL CARDIOL 1999 33 2 Abs 1104-74
11. 345359 Corvas launches second phase II clinical trial for injectable anticoagulant, rNAPc2. Corvas International Inc PRESS RELEASE 1999 October 28
12. Leiden and antiphospholipid syndrome. Bergum PW, Cruikshank AA, Maki SL BLOOD 1999 94 10 3616
13. 350954 Annual Report 1998 - Corvas International Inc. Corvas International Inc ANNUAL REPORT 1998 December 31
14. 350959 The potent, Factor Xa-dependent inhibition by rNAPc2 of Factor VIIa (FVIIa)/tissue factor involves the binding of its cofactor to a exosite on FVIIa, followed by occupation of the active site. Bergum P, Cruikshank A, Maki S, Ruf W, Vlasuk G BLOOD 1998 92 10 Suppl 1 669A
15. 394178 A dose-response study of the Factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty. Agnelli G, Lee A, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Gent M BLOOD 2000 96 11 Suppl 1 Abs 2114
16. 400490 Corvas reports fourth quarter and year-end results. Corvas International Inc PRESS RELEASE 2001 February 28
17. 416718 Corvas reports second quarter results; company also announces update on clinical trial plans for rNAPc2. Corvas International Inc PRESS RELEASE 2001 July 24
18. 423854 Corvas International Inc - Corvas strengthens its focus on cancer; company update. Augustine ME US BANCORP PIPER JAFFREY INC 2001 September 21
19. 426625 Corvas International reports third quarter results. Corvas International Inc PRESS RELEASE 2001 October 23
20. 431336 Corvas reports Q3:01 results, plans NAPc2 unstable angina phase II study for 2002, will not pursue DVT development without partner. Augustine M, Troyer R US BANCORP PIPER JAFFRAY INC 2001 October 24
21. 432360 Corvas International presents results of phase IIa clinical trial of rNAPc2 anticoagulant in elective angioplasty. Corvas International Inc PRESS RELEASE 2001 December 05
22. 432562 Exosite-binding contributes significantly to the potent inhibition of Factor Xa by tissue factor pathway inhibitor. Krishnaswamy S, Broze GJ, Vlasuk GP, Wilkens M BLOOD 2001 98 11 Suppl 1 Abs 2209
23. 433016 A blinded, dose-escalation phase IIa study of the FVIIa/tissue factor inhibitor rNAPc2 in patients undergoing elective percutaneous coronary angioplasty. Moons A, Bijsterveld N, Bueller H, Prins M, Rote WE, Vlasuk GP, Peters RJ BLOOD 2001 98 11 Suppl 1 Abs 2955
24. 434478 American Society of Hematology - 43rd Annual Meeting (Part VI), Orlando, FL, USA. Clemetson K IDDB MEETING REPORT 2001 December 7-11
25. 465759 BioPartnering - Corvas International Inc. ANN BIOPARTNERING EUROPE MEET 2002 10 October 13-15
26. 466967 rNAPc2 - a recombinant protein for the treatment of acute coronary syndromes. Corvas International Inc COMPANY PUBLICATION 2002 October 15
27. 469165 Corvas initiates phase II clinical program for its novel anticoagulant rNAPc2 in patients with acute coronary syndromes. Corvas International Inc PRESS RELEASE 2002 November 05
28. 473059 Recombinant nematode anticoagulant protein c2 (rNAPc2), an inhibitor of tissue factor/Factor VIIa, attenuates coagulation and the IL10 response in human endotoxemia. de Pont A CJM, Moons AHM, de Jonge E, Meijers JCM, van der Poll T, Vlasuk GP, Rote WE, Vroom MB, Buller HR, Levi M BLOOD 2002 100 11 Abs 1892
29. 484147 Factor Xa inhibitors: Today and beyond. Walenga JM, Jeske WP, Hoppensteadt D, Fareed J CURR OPIN INVEST DRUGS 2003 4 3 272-281
30. 484476 Securities and Exchange Commission: Form 10-K. Corvas International Inc COMPANY WORLD WIDE WEB SITE 2002 December 31
31. 492192 Activation of coagulation by administration of recombinant Factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. de Jonge E, Friederich PW, Vlasuk GP, Rote WE, Vroom MB, Levi M, van der Poll T CLIN DIAGN LAB IMMUNOL 2003 10 3 495-497
32. 492228 Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-Factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Moons AHM, Peters RJG, Cate H, Bauer KA, Vlasuk GP, Buller HR, Levi M THROMB HAEMOST 2002 88 4 627-631
33. 492278 A blinded multicenter dose escalation phase IIa study of the Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in patients undergoing elective percutaneous coronary intervention. Moons AH, Bijsterveld NR, Buller HR, Prins MH, Rote WE, Vlasuk GP, Peters RJ J AM COLL CARDIOL 2002 39 5 16A
34. 492284 Ability of recombinant Factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR CIRCULATION 2001 103 21 2555-2559
35. 492288 Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van der Meer J et al CIRCULATION 2001 104 1 74-78
36. 492294 A dose-response study of the Factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty. Lee A, Agnelli G, Bueller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Gent M BLOOD 2000 96 11 Pt 1 491a
37. 512031 The sixth ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. Hirsh J, Dalen JE, Guyatt GMD CHEST 2001 119 Suppl 1 1S-2S
38. 513610 A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. Toso R, Pinotti M, High KA, Pollak ES, Bernardi F BIOCHEM J 2002 363 2 411-416
39. 513686 Tissue factor/Factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS CANCER RES 2003 63 11 2997-3000
40. 517773 Treatment of Ebola virus infection with a recombinant inhibitor of Factor VIIa/tissue factor: A study in rhesus monkeys. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP LANCET 2003 362 9400 1953-1958
41. 517775 Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE J INFECT DIS 2003 188 11 1618-1629
42. 521049 Nuvelo licenses rNAPc2, a novel anticoagulant, from Dendreon. Nuvelo Inc PRESS RELEASE 2004 February 04